Parameter
| Biomarker | ALK | Full name | Anaplastic Lymphoma Kinase | Molecular Type | Nucleic acid（DNA） |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Targeted therapy guidance |
| Disease | Non-Small Cell Lung Cancer | Disease Subtypes | / | ||
| Organ | Lung | Test Sample / Technology Platform | Tissue / Blood (Genetic Testing) | ||
| Pathobiological Mechanisms | Fusion genes cause tumorigenesis and can be specifically inhibited by ALK inhibitors | ||||
| Clinical Availability Status | Clinically available (targeted therapy screening) | ||||
| Notes and Dynamics | The incidence is 3% to 7%, and it is more common in young, non-smokers, or light smokers with lung adenocarcinoma | ||||